Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET.
加利福尼亚州埃默里维尔,2024年11月26日 /PRNewswire/ — 开发和商业化创新疫苗的商业阶段生物制药公司戴纳瓦克斯科技公司(纳斯达克股票代码:DVAX)今天宣布,该公司将于美国东部时间12月3日星期二下午2点35分出席第七届Evercore HealthConx年度会议。
The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at .
该演示将进行网络直播,可通过公司网站 “投资者” 部分的 “活动与演讲” 页面进行访问,网址为。
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018 adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit .
关于 Dynavax
Dynavax是一家处于商业阶段的生物制药公司,正在开发和商业化创新疫苗,以帮助保护世界免受传染病的侵害。该公司有两种商业产品,HepliSav-B疫苗 [乙型肝炎疫苗(重组),佐剂],已获美国、欧盟和英国批准,用于预防18岁及以上成年人由所有已知的乙型肝炎病毒亚型引起的感染,以及CpG 1018佐剂,目前用于 HeplisaV-B 和多种佐剂 COVID-19 疫苗。有关我们的上市产品和开发渠道的更多信息,请访问。
For Investors/Media:
Paul Cox
[email protected]
510-665-0499
对于投资者/媒体:
保罗·考克斯
[电子邮件保护]
510-665-0499
Nicole Arndt
[email protected]
510-665-7264
妮可·阿恩特
[电子邮件保护]
510-665-7264
SOURCE Dynavax Technologies
来源 Dynavax 科技